Discussion on critical points for a tailored therapy to cure hepatitis C virus infection
Hepatitis C virus (HCV) infects around 71 million people worldwide and in 2018 it is still a major health problem. Since 2011, anti-HCV therapy with availability of direct-acting antiviral drugs has revolutionized the clinical response and paved the way to eradication strategies. However, despite th...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Association for the Study of the Liver
2019-03-01
|
Series: | Clinical and Molecular Hepatology |
Subjects: | |
Online Access: | http://e-cmh.org/upload/pdf/cmh-2018-0061.pdf |
id |
doaj-6de52accaeb7417ba29718bc7ac51aee |
---|---|
record_format |
Article |
spelling |
doaj-6de52accaeb7417ba29718bc7ac51aee2020-11-25T01:55:01ZengKorean Association for the Study of the LiverClinical and Molecular Hepatology2287-27282287-285X2019-03-01251303610.3350/cmh.2018.00611445Discussion on critical points for a tailored therapy to cure hepatitis C virus infectionNadia Marascio0Angela Quirino1Giorgio Settimo Barreca2Luisa Galati3Chiara Costa4Vincenzo Pisani5Maria Mazzitelli6Giovanni Matera7Maria Carla Liberto8Alfredo Focà9Carlo Torti10 Department of Health Sciences, Unit of Clinical Microbiology, Unit of Infectious and Tropical Diseases, Magna Graecia University, Catanzaro, Italy Department of Health Sciences, Unit of Clinical Microbiology, Unit of Infectious and Tropical Diseases, Magna Graecia University, Catanzaro, Italy Department of Health Sciences, Unit of Clinical Microbiology, Unit of Infectious and Tropical Diseases, Magna Graecia University, Catanzaro, Italy Department of Health Sciences, Unit of Clinical Microbiology, Unit of Infectious and Tropical Diseases, Magna Graecia University, Catanzaro, Italy Department of Health Sciences, Department of Medical and Surgical Sciences, Unit of Infectious and Tropical Diseases, Magna Graecia University, Catanzaro, Italy Department of Health Sciences, Department of Medical and Surgical Sciences, Unit of Infectious and Tropical Diseases, Magna Graecia University, Catanzaro, Italy Department of Health Sciences, Department of Medical and Surgical Sciences, Unit of Infectious and Tropical Diseases, Magna Graecia University, Catanzaro, Italy Department of Health Sciences, Unit of Clinical Microbiology, Unit of Infectious and Tropical Diseases, Magna Graecia University, Catanzaro, Italy Department of Health Sciences, Unit of Clinical Microbiology, Unit of Infectious and Tropical Diseases, Magna Graecia University, Catanzaro, Italy Department of Health Sciences, Unit of Clinical Microbiology, Unit of Infectious and Tropical Diseases, Magna Graecia University, Catanzaro, Italy Department of Health Sciences, Department of Medical and Surgical Sciences, Unit of Infectious and Tropical Diseases, Magna Graecia University, Catanzaro, ItalyHepatitis C virus (HCV) infects around 71 million people worldwide and in 2018 it is still a major health problem. Since 2011, anti-HCV therapy with availability of direct-acting antiviral drugs has revolutionized the clinical response and paved the way to eradication strategies. However, despite the high rate of sustained virological response, treatment failure may occur in a limited percentage of patients, possibly due to resistance-associated substitutions (RASs), either emergent or pre-existent even in minority viral populations. Clearly this problem may impair success of eradication strategies. With this background, several questions marks still exist around HCV treatment, including whether pan-genotypic treatments with complete effectiveness in any clinical conditions really exist outside clinical trials, the actual cost-effectiveness of genotyping testing, and utility of RAS detection in viral quasispecies by next generation sequencing approach. In this review, we describe these critical points by discussing recent literature data and our research experience.http://e-cmh.org/upload/pdf/cmh-2018-0061.pdfDirect-acting antiviralsResistance-associated substitutionsGenetic variationDeep sequencing |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Nadia Marascio Angela Quirino Giorgio Settimo Barreca Luisa Galati Chiara Costa Vincenzo Pisani Maria Mazzitelli Giovanni Matera Maria Carla Liberto Alfredo Focà Carlo Torti |
spellingShingle |
Nadia Marascio Angela Quirino Giorgio Settimo Barreca Luisa Galati Chiara Costa Vincenzo Pisani Maria Mazzitelli Giovanni Matera Maria Carla Liberto Alfredo Focà Carlo Torti Discussion on critical points for a tailored therapy to cure hepatitis C virus infection Clinical and Molecular Hepatology Direct-acting antivirals Resistance-associated substitutions Genetic variation Deep sequencing |
author_facet |
Nadia Marascio Angela Quirino Giorgio Settimo Barreca Luisa Galati Chiara Costa Vincenzo Pisani Maria Mazzitelli Giovanni Matera Maria Carla Liberto Alfredo Focà Carlo Torti |
author_sort |
Nadia Marascio |
title |
Discussion on critical points for a tailored therapy to cure hepatitis C virus infection |
title_short |
Discussion on critical points for a tailored therapy to cure hepatitis C virus infection |
title_full |
Discussion on critical points for a tailored therapy to cure hepatitis C virus infection |
title_fullStr |
Discussion on critical points for a tailored therapy to cure hepatitis C virus infection |
title_full_unstemmed |
Discussion on critical points for a tailored therapy to cure hepatitis C virus infection |
title_sort |
discussion on critical points for a tailored therapy to cure hepatitis c virus infection |
publisher |
Korean Association for the Study of the Liver |
series |
Clinical and Molecular Hepatology |
issn |
2287-2728 2287-285X |
publishDate |
2019-03-01 |
description |
Hepatitis C virus (HCV) infects around 71 million people worldwide and in 2018 it is still a major health problem. Since 2011, anti-HCV therapy with availability of direct-acting antiviral drugs has revolutionized the clinical response and paved the way to eradication strategies. However, despite the high rate of sustained virological response, treatment failure may occur in a limited percentage of patients, possibly due to resistance-associated substitutions (RASs), either emergent or pre-existent even in minority viral populations. Clearly this problem may impair success of eradication strategies. With this background, several questions marks still exist around HCV treatment, including whether pan-genotypic treatments with complete effectiveness in any clinical conditions really exist outside clinical trials, the actual cost-effectiveness of genotyping testing, and utility of RAS detection in viral quasispecies by next generation sequencing approach. In this review, we describe these critical points by discussing recent literature data and our research experience. |
topic |
Direct-acting antivirals Resistance-associated substitutions Genetic variation Deep sequencing |
url |
http://e-cmh.org/upload/pdf/cmh-2018-0061.pdf |
work_keys_str_mv |
AT nadiamarascio discussiononcriticalpointsforatailoredtherapytocurehepatitiscvirusinfection AT angelaquirino discussiononcriticalpointsforatailoredtherapytocurehepatitiscvirusinfection AT giorgiosettimobarreca discussiononcriticalpointsforatailoredtherapytocurehepatitiscvirusinfection AT luisagalati discussiononcriticalpointsforatailoredtherapytocurehepatitiscvirusinfection AT chiaracosta discussiononcriticalpointsforatailoredtherapytocurehepatitiscvirusinfection AT vincenzopisani discussiononcriticalpointsforatailoredtherapytocurehepatitiscvirusinfection AT mariamazzitelli discussiononcriticalpointsforatailoredtherapytocurehepatitiscvirusinfection AT giovannimatera discussiononcriticalpointsforatailoredtherapytocurehepatitiscvirusinfection AT mariacarlaliberto discussiononcriticalpointsforatailoredtherapytocurehepatitiscvirusinfection AT alfredofoca discussiononcriticalpointsforatailoredtherapytocurehepatitiscvirusinfection AT carlotorti discussiononcriticalpointsforatailoredtherapytocurehepatitiscvirusinfection |
_version_ |
1724985705808003072 |